Back to Search
Start Over
Colon Surgery Risk With Corticosteroids Versus Immunomodulators or Biologics in Inflammatory Bowel Disease Patients With Clostridium difficile Infection.
- Source :
-
Inflammatory bowel diseases [Inflamm Bowel Dis] 2019 Feb 21; Vol. 25 (3), pp. 610-619. - Publication Year :
- 2019
-
Abstract
- Background: Inflammatory bowel disease (IBD) is an independent risk factor for Clostridium difficile infection (CDI), and CDI often precipitates IBD exacerbation. Because CDI cannot be distinguished clinically from an IBD exacerbation, management is difficult. We aimed to assess factors associated with adverse outcomes in IBD with CDI, including the role of escalating or de-escalating IBD therapy and CDI treatment.<br />Methods: Records for patients with IBD and CDI from 2008 to 2013 were abstracted for variables including IBD severity before CDI diagnosis, CDI management, subsequent IBD exacerbation, CDI recurrence, and colon surgery. Colon surgery was defined as resection of any colonic segment within 1 year after CDI diagnosis.<br />Results: We included 137 IBD patients (median age, 46 years; 55% women): 70 with ulcerative colitis (51%), 63 with Crohn's disease (46%), and 4 with indeterminate colitis (3%). Overall, 70% of CDIs were mild-moderate, 14% were severe, and 15% were severe-complicated. Clostridium difficile infection treatment choice did not vary by infection severity (P = 0.27). Corticosteroid escalation (odds ratio [OR], 5.94; 95% confidence interval [CI], 2.03-17.44) was a positive predictor of colon surgery within 1 year after CDI; older age (OR, 0.09; 95% CI, 0.01-0.44) was a negative predictor. Modifying the corticosteroid regimen did not affect CDI recurrence or risk of future IBD exacerbation. Adverse outcomes did not differ with CDI antibiotic regimens or biologic or immunomodulator regimen modification.<br />Conclusions: Corticosteroid escalation for IBD during CDI was associated with higher risk of colon surgery. Type of CDI treatment did not influence IBD outcomes. Prospective studies are needed to further elucidate optimal management in this high-risk population.<br /> (© 2018 Crohn’s & Colitis Foundation. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Subjects :
- Adult
Aged
Aged, 80 and over
Clostridium Infections epidemiology
Clostridium Infections microbiology
Female
Follow-Up Studies
Humans
Male
Middle Aged
Minnesota epidemiology
Prognosis
Retrospective Studies
Risk Factors
Young Adult
Adrenal Cortex Hormones adverse effects
Biological Products adverse effects
Clostridioides difficile isolation & purification
Clostridium Infections therapy
Colectomy statistics & numerical data
Immunologic Factors adverse effects
Inflammatory Bowel Diseases complications
Subjects
Details
- Language :
- English
- ISSN :
- 1536-4844
- Volume :
- 25
- Issue :
- 3
- Database :
- MEDLINE
- Journal :
- Inflammatory bowel diseases
- Publication Type :
- Academic Journal
- Accession number :
- 30260451
- Full Text :
- https://doi.org/10.1093/ibd/izy291